Experimental Alzheimer’s Treatment Targets DNA Damage and Brain Inflammation
Key Points
- KCL-286, originally developed for spinal cord injuries, repaired DNA damage and reduced inflammation in a mouse model of Alzheimer's.
- The orally bioavailable small molecule targets multiple early disease pathways, not just toxic protein buildup.
- KCL-286 has already cleared Phase 1 human safety trials, potentially shortening the path to further clinical testing.
Scientists at King’s College London have identified a promising new strategy for fighting Alzheimer’s disease that could address several of the condition’s damaging effects at the same time. Their research suggests that an experimental drug originally developed for spinal cord injuries may help repair damaged DNA, reduce inflammation, and target biological changes associated with the disease.
The drug, known as KCL-286, produced encouraging results in a mouse model of Alzheimer’s disease. Unlike treatments that focus primarily on the buildup of toxic proteins in the brain, this approach targets additional processes that can begin long before the disease reaches its advanced stages.
One particularly promising advantage is that KCL-286 has already completed Phase 1 human safety and tolerability trials as part of its earlier development. This could significantly shorten the path toward further clinical testing, although its effectiveness against Alzheimer’s in humans has not yet been established.
“KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development,” commented Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London.
The drug is a small molecule that can be taken by mouth, making it potentially more convenient to administer than treatments that require injections or infusions.
Natasha Hill, one of the first authors on the paper, said: “To develop an effective treatment for Alzheimer’s disease, we need to tackle multiple aspects of the disease. KCL-286 was able to target multiple disease-relevant cellular pathways, some of which are initiated very early in the disease course.”
Source: King’s College London. “Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation.” ScienceDaily. ScienceDaily, 2 November 2026. www.sciencedaily.com/releases/2026/11/261102075806.htm
Total Page Views: 3
